AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Business

After Rova-T Failure, A Look at AbbVie’s Pipeline

Analysts look at what else AbbVie has in the pipeline after Rova-T Failure.

March 27, 2018

2 min read

Mark Terry

Business

Ablynx Drug Fails Again in Mid-Stage Trial

For the second time Ablynx’s anti-IL-6R Nanobody, vobarilizumab has failed to pass muster. This morning Belgium-based company said vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.

March 26, 2018

2 min read

Alex Keown

Drug Development

Poor Mid-Stage Results Sink AbbVie’s Plans for Cancer Drug

After disappointing mid-stage results and discussions with the FDA, AbbVie will not ask for accelerated approval for its lung cancer drug.

March 22, 2018

2 min read

Mark Terry

FDA

Eli Lilly Gets Another Shot at FDA Approval for RA Drug

On April 23, the FDA’s arthritis advisory committee will take another look at Eli Lilly’s re-submission for their moderate-to-severe rheumatoid arthritis drug.

March 15, 2018

2 min read

Mark Terry